Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial

Table 3 Post-hoc analysis of mGFR change by excluding patients who had an outlier mGFR result (ANCOVA)

	mGFR (mL/min/1.73 m ² )
	Tofacitinib → placebo group	Placebo → placebo group
Change at end of period 1 from baseline
Number	76	37
Adjusted geometric mean fold-change (90% CI)	0.91 (0.88, 0.93)	1.01 (0.97, 1.04)
Ratio of adjusted geometric mean fold-change (90% CI)	0.90 (0.86, 0.94)
Change at end of period 2 from baseline
Number	72	36
Adjusted geometric mean fold-change (90% CI)	0.96 (0.93, 0.99)	0.98 (0.94, 1.01)
Ratio of adjusted geometric mean fold-change (90% CI)	0.98 (0.94, 1.03)
Change at end of period 2 from end of period 1
Number	72	36
Adjusted geometric mean fold-change (90% CI)	1.06 (1.03, 1.09)	0.99 (0.95, 1.03)
Ratio of adjusted geometric mean fold-change (90% CI)	1.07 (1.02, 1.12)

Post-hoc analysis excluded those patients with a difference between mGFR and eGFR falling outside the 95% limits of agreement between the two methods of measurement. ANCOVA, analysis of covariance; eGFR, estimated glomerular filtration rate; mGFR, measured glomerular filtration rate.

ISSN: 1478-6362